Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FTC Blocks Australian CSL’s Acquisition of Talecris, Noting Consolidation Would Reduce Competition

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - The U.S. Federal Trade Commission has authorized a lawsuit to stop Australian-based CSL Limited's $3.1 billion acquisition of Talecris Biotherapeutics, charging that the deal "would be illegal and would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies," the commission announced May 27

You may also be interested in...



CSL Highlights Gum Disease Vaccine Partnership With Sanofi Pasteur And Acute Heart Disease Compound At R&D Briefing

PERTH, Australia - Melbourne-based CSL Limited focused on two new products about to enter the clinic during its Dec. 10 R&D briefing, including a new vaccine to treat severe gum disease, which it is co-developing with Sanofi Pasteur

CSL Highlights Gum Disease Vaccine Partnership With Sanofi Pasteur And Acute Heart Disease Compound At R&D Briefing

PERTH, Australia - Melbourne-based CSL Limited focused on two new products about to enter the clinic during its Dec. 10 R&D briefing, including a new vaccine to treat severe gum disease, which it is co-developing with Sanofi Pasteur

CSL Highlights Gum Disease Vaccine Partnership With Sanofi Pasteur, Cardio Drug, During R&D Update

Research suggests periodontal disease leads to systemic threats, including cardiovascular disease, oropharyngeal and pancreatic cancers and diabetes, expert says.

Related Content

UsernamePublicRestriction

Register

PS141439

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel